Characteristics of the subjects randomised to the two treatment arms
| Phase I | Phase II | ||||
|---|---|---|---|---|---|
|
Placebo (n = 22) | Salbutamol (n = 21) |
Placebo (n = 21) |
Beclo- methasone (n = 22) | ||
| Median age (range), years | 8.5 (6–15) | 10.2 (6–17) | 9.2 (6–15) | 8.5 (6–17) | |
| Sex (M:F) | 11:11 | 8:13 | 7:14 | 12:10 | |
| Period of current cough, weeks1-150 | 8 (8.3) | 8 (10.5) | 12 (7.5) | 7 (9) | |
| History of recurrent cough, months1-150 | 24 (27) | 24 (26) | 24 (31) | 24 (36) | |
| Smoke exposure (n) | 5 | 8 | 8 | 5 | |
| History of past wheeze (n) | 11 | 13 | 12 | 12 | |
| Eczema (n) | 4 | 4 | 3 | 5 | |
| Atopy (n) | 10 | 15 | 11 | 14 | |
| Airway hyperresponsiveness (n) | 8 | 6 | 4 | 10 | |
| Family history of asthma (n) | 14 | 13 | 14 | 13 | |
| Family history of atopy (n) | 17 | 16 | 16 | 17 | |
| FEV1 %predicted (SE) | 98 (3) | 109 (4) | 101 (4) | 104 (3) | |
| FVC %predicted (SE) | 101 (2) | 109 (3) | 104 (3) | 105 (2) | |
There was no significant difference between the two groups for any variable in either phase.
↵1-150 Median (interquartile range).